# Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

> **Open Intelligence Dossier** · First detected: 2026-06-23 17:07 UTC · Category: Business

## Executive Summary
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Yahoo Finance, Kalkine Media, CancerNetwork and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxONXNxb3dkYXhCUXBfY21uZ2c5dDY1UTQ3emZlVnpaZTExRDI1bHp6XzY4ZHM4YkJrVkdjajJkU1dxLWdQQWg1NTQ4eGZ6WmNzSi1kZ2t6aWdjV1cwbGdHSzZ0SEJzSmFEc0o2MjM1N0tmRnhLalBBTnM4NlRsc0xjTzVWOGRIekxjeHJ4ZEtEa05jMWs?oc=5) |
| Kalkine Media | Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxPdy12OTNHdTZudXJaWXRVaVZiRzRLLTUwVG54N3BBeWNSOTdJeG9xZy1hQUtTRlhnTW9tOEJkbnpuck9LZkRablI4RzIxRnJaaHZUTDF4aWhzaW5XU00xblg2Z21tSWt3LUFWUnMwUTZoRlVRTUVhV0YyY0ZxOS1uN2lyRGtyQkFpazhacUZPS3hLRGNFMVJWdUpmYjlfdw?oc=5) |
| CancerNetwork | Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNcDV1WVRhLVhGY2NRLWdNVHJod2NHbVlnOFhIcm9LakZubk1SU3AzandubWpWdGU4WkFxZEc0V05DZi1YWUg0aEMwX2FhVy1Od0tiZzRDRFlBWVFpTUhwV3NmUkszZ2dMRzVmNHVla0t0cUJQQjhyMnRaZXJQS1F6M0VwR09LZkM3ZlVKV3lwcEstcl9SODlQVlByNVN6dVlQTmljRXZXeXdGRHF6?oc=5) |
| BioPharma Dive | Pfizer drug acquired in Seagen deal disappoints in lung cancer study | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxNWkFfUV9pVjVZRFJqQ0JHRXM5VHVNMEsyVko0VDhybTRYVC1LWVhJS2lLR0xOenRlRGM3aXk5enhYQUgzdFRJMEJsaEZocDZkVkRqQUNkT3Bwdkc2Yy14RVJtYXpKVktWOC0yUGtaS040dmUwNFFkeXB0T2M5SjhHUFB5YUtCSC1QRXhZdGdPWkl4ZDN1LUszbnBsQQ?oc=5) |
| OncLive | Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxQYlQ2aDNQdjhNZXNRNFpWUFRxQ204NjRCbVU1RmJBZklscGJIampZTEZwc25sdjdOTW53d1Z0UEdkN09TUVhDM0txampGSEtWVmZhUnlkZDYxME9kVFFEWUtpNjgwZ3dUclVWLXQ0aUdheHVyRTZiZFVUVnRSWjJ4VlVHRlpya2pzNTZ5VGZrYWJRUXlLcmJ1SnJpc3NvWmZ2dVZKYlNkbmhIOHd5?oc=5) |
| Endpoints News | Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNcG5fWWpvWDNFZWM0OEUxbmgtbU0wTDgzQjNQTE12QkVMdTFlMlliUFlwTkNsbUY4T0FPYXdONkx6cWU1a3pxSWJ2UjcwLUgxQWJuVnFBdG9ya2VmV1hVRmkyRXhqelp4ckFqY0JlcVBqR29WMzg5cWR1VVpfNUU1cjVZVXVfRXlsNmt0X2phVmRiQ05BMXhESVJRMmw5YlE?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-06-23/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial*